MindWalk Holdings Corp Stock Price, News & Analysis

MindWalk (Nasdaq: HYFT) announced discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in ALS, frontotemporal dementia and some Alzheimer’s disease cases. The work shows the company’s platform can distinguish toxic protein conformations from healthy forms and anchors those findings with bio-native wet-lab validation. MindWalk says this validates its platform strategy and reinforces its position as a discovery partner for complex neurodegenerative programs. The study is available on bioRxiv (DOI: 10.1101/2025.06.10.658846).

MindWalk (NASDAQ:HYFT) reports a functional insight in its universal influenza program: a HYFT-defined functional constraint observed across influenza A and B despite sequence variation. MindWalk says this pattern was validated in human H3N2 (including subclade K), avian H5/H7/H9, swine H1N1, and influenza B (Victoria and Yamagata). The company plans further pre-clinical validation and IND-enabling work within a segregated program portfolio, then aims to out-license or partner for late-stage development.

MindWalk (NASDAQ:HYFT) announced a discovery of a persistent functional constraint in influenza biology identified using its patented HYFT Deep Data technology. The company reports the HYFT-defined pattern is conserved across human influenza A (including H3N2 and H3N2 subclade K), avian A subtypes H5, H7, H9, swine-origin H1N1, and influenza B lineages Victoria and Yamagata. MindWalk says this constraint reflects biophysical requirements for infection rather than conserved sequence, and plans further preclinical and IND-enabling work with an out-licensing or strategic-partnering strategy for the program.

MindWalk (NASDAQ: HYFT) reported Q2 fiscal 2026 results and strategic progress on its AI-driven pipeline on December 15, 2025. Key financials: Revenue $4.1M (+54% YoY, +30% sequential), gross margin 65% (from 51%), gross profit $2.7M (+94% YoY), adjusted EBITDA loss improved to $2.4M, and operating loss excluding amortization improved to $2.8M. Cash and cash equivalents were $16.5M, including proceeds from the sale of Netherlands operations.

Strategic updates: AI-designed GLP1 receptor agonist showed in vitro activation above semaglutide; a companion longevity pathway was identified; a conserved dengue epitope was discovered with preclinical planning underway; the company completed a rebrand, appointed a new CFO and CBO, closed a Netherlands divestiture for $14.3M, and initiated a Cayman structure to ringfence AI program portfolios with investor interest ahead of a January 12, 2026 strategic update.

MindWalk Holdings (NASDAQ:HYFT) will release second quarter fiscal 2026 financial results and host a live webcast and conference call on December 15, 2025 at 10:30 AM ET.

The company said a press release with the quarterly financial results will be issued prior to the call, followed by management remarks and a question-and-answer session. The live webcast and replay will be available via the company investor events page and an attendee URL is provided for access.

Dial-in numbers and a conference ID are provided for participants; investors are encouraged to review the company's periodic reports on sec.gov and sedarplus.com for risk factors and historical results.

MindWalk (Nasdaq: HYFT) announced that CTO Dr. Dirk Van Hyfte will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025 on November 20, 2025, 12:15 PM–12:45 PM. Dr. Van Hyfte will discuss how MindWalk’s HYFT®-powered LensAi™ platform indexes, connects, and continuously updates biological knowledge to support AI-driven drug discovery. The company frames the appearance as an opportunity to share its Bio-Native AI approach and Deep Data capabilities with industry peers and researchers.

MindWalk (Nasdaq: HYFT) appointed Thomas W. Lynch, Ph.D., as Chief Business Officer effective October 20, 2025 to accelerate commercial expansion of its HYFT-powered Deep Data platform.

Dr. Lynch brings over two decades of biotech and software commercialization experience, including roles at Aldevron and DNASTAR. He led commercial teams tied to Aldevron initiatives that contributed to its $9.6B acquisition by Danaher in 2021. MindWalk said the hire supports scaling global teams and forging strategic partnerships to broaden adoption in pharma and biotech markets.

MindWalk (NASDAQ: HYFT) announced a Board‑authorized share repurchase program to buy up to 2.3 million common shares between October 15, 2025 and October 15, 2026. The authorization equals approximately 5% of the 46,154,188 shares currently outstanding. Purchases may occur on the open market or by other legally permissible means at prevailing market prices, subject to U.S. and Canadian securities rules. The company expects to fund the Program from existing cash, short‑term investments, future cash flows, or financing activities. The Program is discretionary and does not obligate any repurchases; the Board may suspend or change its terms at any time.

MindWalk Holdings (NASDAQ:HYFT) has announced a significant advancement in its AI-designed GLP-1 therapeutics program, unveiling a novel dual-pathway regimen for aging and longevity applications. The company's LensAI™ platform has identified a previously unknown connection between GLP-1 biology and a second pathway crucial for healthy aging.

The breakthrough involves a first-in-class treatment approach combining MindWalk's proprietary companion therapeutic with its GLP-1 receptor agonists (GLP-1RAs). This development targets the longevity therapeutics market, projected to reach $60 billion by 2030. Earlier this year, the company's AI-designed GLP-1 peptides demonstrated performance matching or exceeding semaglutide in receptor activation assays.